Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diagnocure CUR -- Ignore unavailable to you. Want to Upgrade?

To: john.d who wrote (125)	8/4/2001 7:09:30 PM
From: Mr. L. Neufeldt	Respond to of 132

Thanks, must have missed this one. You know....I'll ask the company directly. Financially though, Diagnocure's ImmunoCyt, is only going to contribute about (we hope) $15 million in sales at maximum with a decent return. Testing is still relatively cumbersome, and there in lies the problem. Diagnocure is moving closer to a more automated system and the test is the only one I know of that is based on urine samples. The test you mentioned could also be based on urine (Uro??). Don't know though...I'll have to check into it. Anyways...it's the reference laboratories that do the majority of the testing and it's them that you have to convince to change the method of testing. They're fairly slow to accept Diagnocure's bladder test which has excellent results. I'm not sure this company would have any greater success or failure. Diagnocure's test, I believe, sells for $50US. Cheap compared to what's out there now. Will have to monitor though. Thanks for the heads up on Vysis.